Search

Your search keyword '"A. Viethen"' showing total 584 results
Start Over Author "A. Viethen"
584 results on '"A. Viethen"'

1. Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation

Author

Shelby D. Reed, PhD, Josephine L. Harrington, MD, Daniel P. Morin, MD, MPH, Samir F. Saba, MD, Jay Alan Montgomery, MD, Robert W. Harrison, MD, Daniel R. Frisch, MD, Thomas Viethen, MD, Miriam Tamm, PhD, Jessica Xiao, PharmD, Hardi Mundl, MD, Rosa Coppolecchia, DO, MPH, Jui-Chen Yang, MEM, Matthew J. Wallace, MA, Juan Marcos Gonzalez, PhD, and Manesh R. Patel, MD

Subjects
atrial fibrillation, net clinical benefit, patient-centered drug development, patient preferences, Diseases of the circulatory (Cardiovascular) system, RC666-701, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Background: Quantifying patients’ preferences for health outcomes associated with atrial fibrillation (AF) and its treatments offers a replicable approach to considering the patient perspective in regulatory decision-making. Objective: The authors conducted a preference survey to estimate the relative importance of AF-related events for use in clinical trial analyses to estimate net health benefits with anticoagulants. Methods: The survey included nontechnical descriptions of three severities of stroke, systemic embolism, myocardial infarction (MI) with or without subsequent heart failure (HF), major bleeding, clinically relevant nonmajor bleeding, and death. A best-worst scaling question format was used in which patients were shown 10 sets of four events and asked to select what they considered to be most and least serious. Results: One thousand twenty-eight patients, mean age 69.2 years, 40.4% female, completed the survey. Best-worst scaling importance weights were significantly different across all events except between major bleeding and MI with HF. Death was considered the most serious (reweighted to 1), followed by severe disabling stroke (0.83), then major bleeding (0.53) or MI with HF (0.50), moderate-severity stroke (0.28) and systemic embolism (0.13). Clinically relevant nonmajor bleeding, MI without HF, and minor stroke (0.10, 0.06, and 0.04, respectively) were considered least serious. Events ordered by importance were consistent across age, sex, and race, but relative weights across events varied by sex and race. Conclusions: Patients expressed relatively high levels of concern about major bleeding compared to moderate-severity stroke or systemic embolism, endpoints frequently used in AF trials. Estimated weights could be used in patient-centered net-benefit determinations for AF therapies.

Published
2024
Full Text
View/download PDF

2. Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources

Author

Alexander Hartenstein, Khaled Abdelgawwad, Frank Kleinjung, Stephen Privitera, Thomas Viethen, and Tatsiana Vaitsiakhovich

Subjects
Algorithms, Hemorrhage, Electronic Health Records, Demography. Population. Vital events, HB848-3697
Abstract

Introduction In randomised controlled trials (RCTs), bleeding outcomes are often assessed using definitions provided by the International Society on Thrombosis and Haemostasis (ISTH). Information relating to bleeding events in real-world evidence (RWE) sources are not identified using these definitions. To assist with accurate comparisons between clinical trials and real-world studies, algorithms are required for the identification of ISTH-defined bleeding events in RWE sources. Objectives To present a novel algorithm to identify ISTH-defined major and clinically-relevant non-major (CRNM) bleeding events in a US Electronic Health Record (EHR) database. Methods The ISTH definition for major bleeding was divided into three subclauses: fatal bleeds, critical organ bleeds and symptomatic bleeds associated with haemoglobin reductions. Data elements from EHRs required to identify patients fulfilling these subclauses (algorithm components) were defined according to International Classification of Diseases, 9th and 10th Revisions, Clinical Modification disease codes that describe key bleeding events. Other data providing context to bleeding severity included in the algorithm were: `interaction type' (diagnosis in the inpatient or outpatient setting), `position' (primary/discharge or secondary diagnosis), haemoglobin values from laboratory tests, blood transfusion codes and mortality data. Results In the final algorithm, the components were combined to align with the subclauses of ISTH definitions for major and CRNM bleeds. A matrix was proposed to guide identification of ISTH bleeding events in the EHR database. The matrix categorises bleeding events by combining data from algorithm components, including: diagnosis codes, 'interaction type', 'position', decreases in haemoglobin concentrations (≥2 g/dL over 48 hours) and mortality. Conclusions The novel algorithm proposed here identifies ISTH major and CRNM bleeding events that are commonly investigated in RCTs in a real-world EHR data source. This algorithm could facilitate comparison between the frequency of bleeding outcomes recorded in clinical trials and RWE. Validation of algorithm performance is in progress.

Published
2023
Full Text
View/download PDF

4. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP)

Author

Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, Christina Petlura, Tamara Bazouzi, Kiranbir Josan, Upinder Grewal, Thomas Viethen, Hardi Mundl, Joachim Luithle, Leonard Basobas, Alexis Touros, Michael J. T. Senior, Koen De Lombaert, Kenneth W. Mahaffey, Mintu P. Turakhia, and Rajesh Dash

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Abstract The Coronavirus Disease 2019 (COVID-19) pandemic curtailed clinical trial activity. Decentralized clinical trials (DCTs) can expand trial access and reduce exposure risk but their feasibility remains uncertain. We evaluated DCT feasibility for atrial fibrillation (AF) patients on oral anticoagulation (OAC). DeTAP (Decentralized Trial in Afib Patients, NCT04471623) was a 6-month, single-arm, 100% virtual study of 100 AF patients on OAC aged >55 years, recruited traditionally and through social media. Participants enrolled and participated virtually using a mobile application and remote blood pressure (BP) and six-lead electrocardiogram (ECG) sensors. Four engagement-based primary endpoints included changes in pre- versus end-of-study OAC adherence (OACA), and % completion of televisits, surveys, and ECG and BP measurements. Secondary endpoints included survey-based nuisance bleeding and patient feedback. 100 subjects (mean age 70 years, 44% women, 90% White) were recruited in 28 days (traditional: 6 pts; social media: 94 pts in 12 days with >300 waitlisted). Study engagement was high: 91% televisits, 85% surveys, and 99% ECG and 99% BP measurement completion. OACA was unchanged at 6 months (baseline: 97 ± 9%, 6 months: 96 ± 15%, p = 0.39). In patients with low baseline OACA (

Published
2022
Full Text
View/download PDF

5. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Author

Auer, Johann, Hubauer, Martin, Pandzic, Sead, Preishuber, Eva, Primus-Grabscheit, Carina, Reitgruber, Dietmar, Schmalzer, Florian, Adlbrecht, Christopher, Schober, Andreas, Hajos, Johannes, Keil, Christoph, Schratter, Alexandra, Frick, Matthias, Benda, Magdalena Anna, Mächler, Maximilian, Mutschlechner, Beatrix, Saely, Christoph, Sprenger, Lukas, Lichtenauer, Michael, Eber, Miriam, Hoppe, Uta, Kolbitsch, Tobias, Jirak, Peter Michael, Mirna, Moritz, Schönbauer, Robert, Bergler-Klein, Jutta, Hengstenberg, Christian, Stojkovic, Stefan, Scherr, Daniel, Manninger-Wünscher, Martin, Rohrer, Ursula, Stühlinger, Markus, Schgoer, Wilfried, Schwarzl, Jana, Pürerfellner, Helmut, Derndorfer, Michael, Ebner, Christian, Eder, Veronika, Kollias, Georgios, Sturmberger, Thomas, Sieghartsleitner, Stefan, Vijgen, Johan, Koopman, Peter, Dujardin, Karl, Anné, Wim, De Ceuninck, Michel, Tavernier, Rene, Duytschaever, Mattias, Knecht, Sébastien, Missault, Luc, Vandekerckhove, Yves, Rossenbacker, Tom, Ector, Bavo, Charlier, Filip, Debruyne, Philippe, Dewilde, Willem, Janssens, Luc, Roosen, John, Vankelecom, Bart, Heidbuchel, Hein, Delesie, Michiel, Vervoort, Gert, Rombouts, Hans, Vanassche, Thomas, Engelen, Matthias, Verhamme, Peter, Willems, Rik, Constance, Christian, Pranno, Nicolas, Cox, Jafna, Bata, Iqbal, Macle, Laurent, Aguilar, Martin, Tourigny, Julia Cadrin, Dubuc, Marc, Dyrda, Katia, Guerra, Peter, Khairy, Paul, Mondésert, Blandine, Rivard, Léna, Roy, Denis, Tadros, Rafik, Talajic, Mario, Thibault, Bernard, Nault, Isabelle, Blier, Louis, Champagne, Jean, Molin, Franck, O'Hara, Gilles, Philippon, François, Plourde, Benoit, Sarrazin, Jean-François, Steinberg, Christian, Coufal, Zdenek, Balazsik, David, Mikulica, Michal, Zapeca, Jakub, Cermak, Ondrej, Drasnar, Tomas, Falc, Matej, Hornof, Josef, Racz, Blazej, Weissova, Danica, Linkova, Hana, Paskova, Eva, Petr, Robert, Sirakova, Andrea, Kettner, Jiri, Benak, Ales, Holek, Martin, Podpera, Ivo, Podperova, Monika, Vancura, Vlastimil, Jandik, Tomas, Smid, Jiri, Dedek, Vratislav, Banik, Jan, Durdil, Vaclav, Hnat, Tomas, Lellouche, Nicolas, Rouffiac, Ségolène, Taldir, Guillaume, Bridonneau, Valentin, Couffon, Philippe, Daudin, Magalie, Hamon, Cécile, Lacaze, Jonathan, Quentin, Anne, Thebault, Christophe, Boiffard, Emmanuel, Billon, Olivier, Miette, Fabien, Pouliquen, Hervé, Turlotte, Guillaume, Gorka, Hervé, Albert, Franck, Bayle, Sandrine, Bensaid, Reda, Dasoveanu, Madalina, Demichili, Thibaud, Dutoiu, Teodora, Khalil, Cliff, Loghin, Caterina, Range, Grégoire, Roussel, Laurent, Socié, Pierre, Thuaire, Christophe, Extramiana, Fabrice, Algalarrondo, Vincent, Boughanmi, Haten, El Mansour, Noreddine, Mohammad, Usman, Sellier, Romain, Elbaz, Meyer, Laperche, Clémence, Maury, Philippe, Kiss, Robert, Borsanyi, Tunde, Gingl, Zoltan, Polgar, Balaza, Benczur, Bela, Bodor, Alexandra, Hepp, Tamas, Malati, Eva, Nagy, Laszlo, Erdei, Norbert, Kapus, Jozsef, Kapus, Katalin, Toth, Brigitta, Matoltsy, Andras, Kiss, Tunde, Merkely, Bela, Herczeg, Szilvia, Kiss, Orsolya, Sallo, Zoltan, Toth, Kalman, Habon, Tamas, Rabai, Miklos, Totsimon, Kinga, Zilahi, Zsolt, Bencze, Gabriella, Santa, Janos, Aradi, Daniel, Kelemen, Barbara, Bolognese, Leonardo, Nesti, Martina, Notarstefano, Pasquale Giovanni, D'Orazio, Simona, Cosmi, Franco, Becattini, Cecilia, Agnelli, Giancarlo, Broccatelli, Belinda, Mosconi, Maria Giulia, Paciaroni, Maurizio, Urbini, Chiara, Parato, Vito Maurizio, Notaristefani, Camilla, Scarano, Michele, Ameri, Pietro, Ghigliotti, Giorgio, Guglielmi, Giulia, Lotti, Roberta, Merlo, Andrea Carlo, Muiesan, Maria Lorenza, Abondio, Andrea, Berasi, Caterina, Mattiuzzo, Elena, Mutti, Claudio, Salvetti, Massimo, Pignatelli, Pasquale, Menichelli, Danilo, Pastori, Daniele, Tamiya, Eiji, Matsumoto, Takahiro, Takabe, Tomosato, Yamamoto, Shoichi, Yamashita, Haruyo, Higashiue, Shinichi, Furuya, Onichi, Hiramatsu, Norihiko, Kasuga, Kensuke, Kojima, Saburo, Komooka, Masatoshi, Kuroyanagi, Satoshi, Matsuura, Makoto, Takemoto, Tetsushi, Yamamoto, Shuji, Saito, Katusmi, Abe, Takuro, Ishida, Issei, Iwanami, Yuji, Kataoka, Shohei, Moriyama, Tetsu, Murohashi, Akira, Sasaki, Akihito, Nakamura, Yuichiro, Ueno, Tetsuya, Shimane, Akira, Hamana, Tomoyo, Ichibori, Hirotoshi, Inoue, Tomohiro, Itoh, Mitsuaki, Iwane, Seigo, Kawai, Hiroya, Kokawa, Tatsuya, Masumoto, Akiko, Matsuo, Koki, Miyata, Taishi, Nakano, Shinsuke, Oishi, Shogo, Onishi, Tetsuari, Sawada, Takahiro, Saito, Takayuki, Shoda, Mitsuhiko, Takahashi, Nobuyuki, Takaya, Tomofumi, Taniguchi, Yasuyo, Tsukamoto, Shota, Tsukishiro, Yasue, Tsukiyama, Yoshiro, Tsunamoto, Hiroshi, Uzu, Kenzo, Yamamoto, Hiroyuki, Yamamoto, Tetsuya, Yokoi, Kiminobu, Yoshida, Chiaki, Watanabe, Nobuhiro, Betsuyaku, Tetsuo, Adachi, Kumiko, Awane, Kouichi, Goto, Daisuke, Sakakibara, Mamoru, Watanabe, Masashi, Ueno, Hideki, Hiroe, Yoshitaka, Matsuo, Koshi, Ayata, Kenji, Fukuda, Ko, Hata, Yoshiki, Hashimoto, Katsushi, Matsumi, Hiroaki, Nikaido, Akira, Okamoto, Shuichi, Sime, Iveta, Stirna, Valters, Reinholde, Ilze, Hansone, Silvija, Kozlovska, Anita, Romanova, Janina, Klincare, Dace, Pontaga, Natalja, Dirmans, Igors, Kalnins, Artis, Upite, Dana, Gersamija, Arcils, Teleznikovs, Arturs, Rozkova, Nadezda, Safro, Jelena, Anguera Camós, Ignasi, Domenico Dallaglio, Paolo, Salguero Bodes, Rafael, Arnbas, Fernando, Borrego, Luis, Marco, Alvaro, Jimenez, Javier Ramos, Gómez-Doblas, Juan José, Pérez Cabeza, Alejandro, Ferreira Gonzålez, Ignacio, Limeres Freire, Javier, Lopez Grau, Merce, Viñolas Prat, Xavier, Moreno Weidmann, Zoraida, Guerra Ramos, Jose Maria, Alonso Martin, Maria Concepcion, Campos Garcia, Bieito, Mogro Carranza, Javier Mauricio, Mendez Zurita, Francisco Javier, Rodriguez Font, Enrique, Gonzales Matos, Carlos Eduardo, García Hernando, Víctor, Lindholm, Carl-Johan, Thulin, Jörgen, Wallén, Håkan, Hagwall, Kristina, Eliasson, Ken, Lundvall, Martin, Olsson, Jens, Kjellman, Björn, Lind, Markus, Johansson, Lars, Svedberg, Niclas, Berglund, Stefan, Söderberg, Julia, Zedigh, Christer, Mooe, Thomas, Axelsson, Mattias, Binsell, Emil, Huber, Daniel, Müller, Christian, Danier, Isabelle, Kühne, Michael, Okamura, Bernhard, Schoepfer, Hadrien, Simmen, Cornelia, Reichlin, Tobias, Chollet, Laurève, Lam, Anna, Wittmer, Severin, Rickli, Hans, Gall, Christian, Hametner, Greta, Intorp, Stephanie, Luescher, Daniel, Haegeli, Laurent, Berg, Jan Christopher, Ebrahimi, Ramin, Auricchio, Angelo, Crljenica, Carmela, Moccetti, Tizziano, Monti, Cristina, Pasotti, Elena, Petrova, Iveta, Rossi, Mariagrazia, Mach, François, Namdar, Mehdi, de Groot, Joris, Proost, Virginnio, Neefs, Joline, Linz, Dominik, van Stipdonk, Twan, den Uijl, Dennis, Alings, Marco, Schaap, Jeroen, Segers, Dolf, Wouters, Noemi, Bartels, Louis, Tieleman, Robert, Pisters, Ron, de Vries, Tim, Selig, Jaap, Kuijper, Aaf, Bot, Pieter, Keijzers, Mitran, Verdel, Gerardus, Tukkie, Raymond, van den Bos, Ewout, Kauer, Floris, Oemrawsingh, Rohit, Stevenhagen, Jeroen, van Es, Jan, Lip, Gregory, Gupta, Dhiraj, Kotalczyk, Agnieszka, Gunstone, Anthony, Brixey, Richard David, Gorog, Diana, Dinarvand, Danial, Gue, Ying, Kanji, Rahim, Memtsas, Vassilios, Senior, Roxy, Bioh, Gabriel, Wong, Yuk-Ki, Child, Nick, Piccini, Jonathan P, Caso, Valeria, Connolly, Stuart J, Fox, Keith A A, Oldgren, Jonas, Jones, W Schuyler, Gorog, Diana A, Durdil, Václav, Viethen, Thomas, Neumann, Christoph, Mundl, Hardi, and Patel, Manesh R

Published
2022
Full Text
View/download PDF

6. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study

Author

Tilmann Kramer, Max Wissmüller, Kristiana Natsina, Felix Gerhardt, Henrik tenFreyhaus, Daniel Dumitrescu, Thomas Viethen, Martin Hellmich, Stephan Baldus, and Stephan Rosenkranz

Subjects
Pulmonary arterial hypertension (PAH), Iron deficiency, Iron, Ferric carboxymaltose, Diseases of the musculoskeletal system, RC925-935, Human anatomy, QM1-695
Abstract

Abstract Background Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates with disease severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral iron on clinical measures warrants further investigation. Methods We retrospectively analysed the long‐term effects of intravenous ferric carboxymaltose (FCM) on iron status and clinical measures in patients with PAH and ID [ferritin

Published
2021
Full Text
View/download PDF

8. Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials

Author

Frank Kramer, Javed Butler, Sanjiv J. Shah, Christian Jung, Savina Nodari, Stephan Rosenkranz, Michele Senni, Luke Bamber, Stephan Cichos, Chrysanthi Dori, Toeresin Karakoyun, Gabriele Jenny Köhler, Kinjal Patel, Paolo Piraino, Thomas Viethen, Praneeth Chennuru, Ayse Paydar, Jason Sims, Richard Clark, Rob van Lummel, Alexandra Müller, Chad Gwaltney, Salko Smajlovic, Hans-Dirk Düngen, and Wilfried Dinh

Subjects
heart failure, activity monitors, patient-reported outcomes, wearables, biomarker, Biology (General), QH301-705.5
Abstract

Aims: Heart failure (HF) affects approximately 26 million people worldwide. With an aging global population, innovative approaches to HF evaluation and management are needed to cope with the worsening HF epidemic. The aim of the Real-Life Multimarker Monitoring in Patients with Heart Failure (REALIsM-HF) study (NCT03507439) is to evaluate a composite instrument comprising remote, real-time, activity-monitoring devices combined with daily electronic patient-reported outcome (ePRO) items in patients who have been hospitalized for HF and are undergoing standard HF assessment (e.g., 6-min walking distance [6MWD], blood biomarkers, Kansas City Cardiomyopathy Questionnaire [KCCQ], and echocardiography). Methods: REALIsM-HF is an ongoing, 12-week, observational study enrolling 80–100 patients aged ≥45 years with HF with preserved ejection fraction (HFpEF; EF ≥45%) or reduced EF (HFrEF; EF ≤35%). Statistical analyses will include examining the association between data from wearables (the AVIVO© mobile patient management patch or VitalPatch© biosensor, and the DynaPort MoveMonitor©), daily ePROs, and conventional HF metrics (e.g., serum/plasma biomarkers, 6MWD, KCCQ, and echocardiographic parameters). The feasibility of and patient compliance with at-home devices will be documented, and the data captured for the purpose of establishing reference values in patients with HFpEF or HFrEF will be summarized. Conclusions: The REALIsM-HF study is to evaluate the longitudinal daily activity profiles of patients with HF and correlate these with changes in serum/plasma biomarker profiles, symptoms, quality of life, and cardiac function and morphology to inform the use of wearable activity monitors for developing novel therapies and managing patients.

Published
2020
Full Text
View/download PDF

9. Zahlungsstromrechnungen von Konzernen

Author

Möller, Hans Peter, Hüfner, Bernd, Keller, Erich, Ketteniß, Holger, Viethen, Heinz W., Möller, Hans Peter, Hüfner, Bernd, Keller, Erich, Ketteniß, Holger, and Viethen, Heinz W.

Published
2018
Full Text
View/download PDF

10. Vollkonsolidierung von Untereinheiten

Author

Möller, Hans Peter, Hüfner, Bernd, Keller, Erich, Ketteniß, Holger, Viethen, Heinz W., Möller, Hans Peter, Hüfner, Bernd, Keller, Erich, Ketteniß, Holger, and Viethen, Heinz W.

Published
2018
Full Text
View/download PDF

20. Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials

Author

Eikelboom, John W., primary, Mundl, Hardi, additional, Alexander, John H., additional, Caso, Valeria, additional, Connolly, Stuart J., additional, Coppolecchia, Rosa, additional, Gebel, Martin, additional, Hart, Robert G., additional, Holberg, Gerlind, additional, Keller, Lars, additional, Patel, Manesh R., additional, Piccini, Jonathan P., additional, Rao, Sunil V., additional, Shoamanesh, Ashkan, additional, Tamm, Miriam, additional, Viethen, Thomas, additional, Yassen, Ashraf, additional, and Bonaca, Marc P., additional

Published
2024
Full Text
View/download PDF

45. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study

Author

Martin Hellmich, Stephan Rosenkranz, Tilmann Kramer, Kristiana Natsina, Felix Gerhardt, Henrik ten Freyhaus, Daniel Dumitrescu, Thomas Viethen, Max Wissmüller, and Stephan Baldus

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Iron, Diseases of the musculoskeletal system, Ferric Compounds, Gastroenterology, FERRIC CARBOXYMALTOSE, Targeted therapy, Physiology (medical), Internal medicine, medicine, Pulmonary arterial hypertension (PAH), Humans, Orthopedics and Sports Medicine, Maltose, Adverse effect, Aged, Retrospective Studies, Pulmonary Arterial Hypertension, Anemia, Iron-Deficiency, biology, medicine.diagnostic_test, Transferrin saturation, business.industry, Iron deficiency, QM1-695, Original Articles, Iron Deficiencies, Middle Aged, medicine.disease, Ferric carboxymaltose, Ferritin, RC925-935, Human anatomy, biology.protein, Serum iron, Original Article, Female, business, Progressive disease
Abstract

Background Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates with disease severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral iron on clinical measures warrants further investigation. Methods We retrospectively analysed the long‐term effects of intravenous ferric carboxymaltose (FCM) on iron status and clinical measures in patients with PAH and ID [ferritin

Published
2021

46. Neue Modularität und Technologie-Roadmapping

Author

Schuh, Günther, Kuhn, Maximilian, Keuper, Alexander, Patzwald, Marc, Schenk, Leonard, Feucht, Michael, Kantelberg, Jan, Rossmair, Georg, Schroth, Herbert, Viethen, Ulrich, Zeller, Paul, and Guo, Daojing

Subjects
DDC::600 Technik, Medizin, angewandte Wissenschaften::620 Ingenieurwissenschaften, Circular economy, Green growth, Technologie-Roadmapping, Produktmodularisierung
Abstract

Durch einen Fokus auf Recycling, geringere Energieverbräuche und verminderten Einsatz umweltschädlicher Rohstoffe kann die Nachhaltigkeit nur bis zu einem gewissen Grad gesteigert werden und erfordert meist die Kompensierung damit einhergehender Kosten. Ein Umdenken und eine radikale Transformation der Wertschöpfung hin zur Zirkularität bieten demgegenüber ökonomische Potenziale, die den Status-Quo deutlich übersteigen. Der Hebel dafür, ist die aktive Verlängerung von Kreisläufen und die Wertsteigerung durch das Upgraden von Produkten während der Nutzungsphase. Dies schafft die Möglichkeit der kontinuierlichen Monetarisierung von Upgrade-Potenzialen, während eine ressourcenausschöpfende Wertsteigerung über die Lebenszyklen eine ganzheitliche ökologische Nachhaltigkeit erreichbar macht. Schlüssel zu diesem Paradigmenwechsel liegen in der Produktmodularisierung und Technologieplanung. Zur Realisierung kreislauffähiger Produkte müssen diese verstärkt integriert und synchronisiert werden. Um heute und morgen ökologische und ökonomisch nachhaltige Leistungen anzubieten, ist ein Verständnis über Märkte und Kunden der Circular Economy notwendig. Außerdem erfordern die regelmäßigen Upgrades ein frühzeitiges Antizipieren relevanter Technologiesprünge. Unter Berücksichtigung dieser beiden Blickrichtungen muss eine Produktarchitektur für kreislauffähige Produkte entwickelt und die Technologiebetrachtung vertikal (um Re-X-Technologien) sowie horizontal (um Remanufacturing und Modul-Upgrades) erweitert werden., By focusing on recycling, lower energy consumption and reduced use of environmentally harmful (raw) materials, sustainability can only be increased to a certain extent and usually requires compensation for the associated costs. In contrast, a change in thinking and a radical transformation of the value creation towards a circular economy offer superior ecological and economic potential. This is realized by an active extension of utilization cycles and the continuous increase in product value through upgrades during the utilization phase, creating the possibility of recurring monetization. Accordingly, the key to this paradigm shift lies in a new product modularization for the realization of a circular economy and in extended technology planning to anticipate the required flexibility and upgrades. Therefore, the goal of modularization is no longer the realization of economies of scale but enabling the value-enhancing extension of product lifetimes through module upgrades and replacements. This means that technology planning should no longer focus exclusively on new products, but in particular also on upgrades for existing products. As a consequence, holistic circularity roadmaps are emerging instead of roadmaps for individual products.

Published
2023
Full Text
View/download PDF

47. New Modularity and Technology Roadmapping

Author

Schuh, Günther, Kuhn, Maximilian, Keuper, Alexander, Patzwald, Marc, Schenk, Leonard, Guo, Daojing, Feucht, Michael, Kantelberg, Jan, Rossmair, Georg, Schroth, Herbert, Viethen, Ulrich, and Zeller, Paul

Subjects
DDC::600 Technik, Medizin, angewandte Wissenschaften::620 Ingenieurwissenschaften, Circular economy, Green growth, Technology planning, Product modularization
Abstract

By focusing on recycling, lower energy consumption and reduced use of environmentally harmful (raw) materials, sustainability can only be increased to a certain extent and usually requires compensation for the associated costs. In contrast, a change in thinking and a radical transformation of the value creation towards a circular economy offer superior ecological and economic potential. This is realized by an active extension of utilization cycles and the continuous increase of product value through upgrades during the utilization phase, creating the possibility of recurring monetization. Accordingly, the key to this paradigm shift lies in a new product modularization for the realization of a circular economy and in an extended technology planning to anticipate the required flexibility and upgrades. Therefore, the goal of modularization is no longer the realization of economies of scale but enabling the value-enhancing extension of product lifetimes through module upgrades and replacements. This means that technology planning should no longer focus exclusively on new products, but in particular also on upgrades for existing products. As a consequence, holistic circularity roadmaps are emerging instead of roadmaps for individual products., Durch einen Fokus auf Recycling, geringere Energieverbräuche und verminderten Einsatz umweltschädlicher Rohstoffe kann die Nachhaltigkeit nur bis zu einem gewissen Grad gesteigert werden und erfordert meist die Kompensierung damit einhergehender Kosten. Ein Umdenken und eine radikale Transformation der Wertschöpfung hin zur Zirkularität bieten demgegenüber ökonomische Potenziale, die den Status-Quo deutlich übersteigen. Der Hebel dafür, ist die aktive Verlängerung von Kreisläufen und die Wertsteigerung durch das Upgraden von Produkten während der Nutzungsphase. Dies schafft die Möglichkeit der kontinuierlichen Monetarisierung von Upgrade-Potenzialen, während eine ressourcenausschöpfende Wertsteigerung über die Lebenszyklen eine ganzheitliche ökologische Nachhaltigkeit erreichbar macht. Schlüssel zu diesem Paradigmenwechsel liegen in der Produktmodularisierung und Technologieplanung. Zur Realisierung kreislauffähiger Produkte müssen diese verstärkt integriert und synchronisiert werden. Um heute und morgen ökologische und ökonomisch nachhaltige Leistungen anzubieten, ist ein Verständnis über Märkte und Kunden der Cir-cular Economy notwendig. Außerdem erfordern die regelmäßigen Upgrades ein frühzei-tiges Antizipieren relevanter Technologiesprünge. Unter Berücksichtigung dieser beiden Blickrichtungen muss eine Produktarchitektur für kreislauffähige Produkte entwickelt und die Technologiebetrachtung vertikal (um Re-X-Technologien) sowie horizontal (um Remanufacturing und Modul-Upgrades) erweitert werden.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results